Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
04:56pm, Wednesday, 28'th Jul 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
09:11am, Tuesday, 15'th Jun 2021
Tuesday's futures were fairly positive after a somewhat mixed start to the week.
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
07:15am, Friday, 11'th Jun 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
07:15am, Wednesday, 09'th Jun 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica
ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
01:52pm, Friday, 04'th Jun 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
07:15am, Thursday, 27'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
07:15am, Wednesday, 26'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
06:15pm, Wednesday, 19'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
07:15am, Monday, 17'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
07:15am, Wednesday, 12'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q1 2021 Results - Earnings Call Transcript
01:57am, Sunday, 09'th May 2021
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q1 2021 Results - Earnings Call Transcript
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
ADC Therapeutics to Participate in May Investor Conferences
07:15am, Tuesday, 04'th May 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic
